LIMINATUS PHARMA INC. *W EXP 04/30/203

LIMINATUS PHARMA INC. *W EXP 04/30/203 is a security (CUSIP 53271X116) tracked across SEC portfolio filings. 24 institutional managers reported $271K on Form 13F as of 2026-06-30; 2 registered fund positions totaling $2K via N-PORT as of 2026-04-30.

Summary

Top institutional holders (Form 13F)

Showing 15 of 24 managers by value.

ManagerLocationValueShares
CLEAR STREET LLCNEW YORK, NY$193K805,477
ARISTEIA CAPITAL LLCGREENWICH, CT$16K319,510
Linden Advisors LPNew York, NY$13K268,199
Saba Capital Management, L.P.NEW YORK, NY$11K233,761
Polar Asset Management Partners Inc.TORONTO, A6$6K122,688
MOORE CAPITAL MANAGEMENT, LPNEW YORK, NY$5K125,000
MMCAP International Inc. SPCGRAND CAYMAN, E9$4K111,745
D. E. Shaw & Co., Inc.New York, NY$3K83,353
MILLENNIUM MANAGEMENT LLCNEW YORK, NY$3K
Cubist Systematic Strategies, LLCStamford, CT$2K15,778
Arena Capital Advisors, LLC- CALOS ANGELES, CA$2K29,166
Blue Owl Capital Holdings LPNew York, NY$2K50,000
Periscope Capital Inc.Toronto, A6$2K47,500
WOLVERINE ASSET MANAGEMENT LLCCHICAGO, IL$2K39,373
TORONTO DOMINION BANKToronto, Ontario, A6$1K35,100

Top fund holders (N-PORT)

FundRegistrantValue% of fund
Saba Capital Income & Opportunities FundSaba Capital Income & Opportunities Fund$2K0.04%
Calamos Market Neutral Income FundCALAMOS INVESTMENT TRUST/IL$3780.00%

More